<DOC>
	<DOCNO>NCT01869803</DOCNO>
	<brief_summary>This clinical trial study gemtuzumab ozogamicin treat patient relapsed refractory acute myeloid leukemia acute promyelocytic leukemia . Monoclonal antibody , gemtuzumab ozogamicin , block cancer growth different way . Some block ability cancer grow spread . Others find cancer cell help kill carry cancer-killing substance .</brief_summary>
	<brief_title>Gemtuzumab Ozogamicin Treating Patients With Relapsed Refractory Acute Myeloid Leukemia Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To provide patient acute myeloid leukemia ( AML ) acute promyelocytic leukemia ( APL ) , relapse refractory standard treatment , access gemtuzumab ozogamicin ( Mylotarg ) comparable satisfactory alternative therapy available . II . To carefully monitor safety report safety information patient receive Mylotarg set . OUTLINE : Patients receive gemtuzumab ozogamicin intravenously ( IV ) 2 hour day 1 15 . After completion study treatment , patient follow every month 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Diagnosis relapse refractory AML candidate standard consolidation treatment daunorubicin cytosine arabinoside OR diagnosis APL relapse tretinoin ( ATRA ) arsenic trioxide therapy APL persist rise blast , comparable satisfactory alternative therapy available ( include patient eligible , access , investigational therapy via clinical trial ) Patients must initial diagnosis AML , biphenotypic acute leukemia , APL Patients must cluster differentiation ( CD ) 33 positivity &gt; 30 % Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 3 / Karnofsky &gt; 60 % Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2 x institutional upper limit normal It deem ethical provide experimental drug ( e.g. , Mylotarg ) associate hepatotoxicity ( venoocclusive disease [ VOD ] ) myelosuppression Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior receive Mylotarg duration treatment ; woman become pregnant suspect pregnant receive treatment Mylotarg , inform treat physician immediately Ability understand willingness sign write Institutional Review Board ( IRB ) approve informed consent document Patients may currently receive investigational agent leukemia Patients know untreated hepatitis C Uncontrolled intercurrent illness include , limited active liver disease , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated Mylotarg Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible ; appropriate study undertake patient receive combination antiretroviral therapy indicate Patients know hypersensitivity gemtuzumab ozogamicin part : recombinant humanize antiCD33 monoclonal ( hP67.6 ) antibody , calicheamicin derivative ingredient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>